This is not a preference
The complementary MOAs of amylin-analog and GLP-1 receptor agonists appear to be a promising combination therapy with greater weight loss than any other currently approved AOM and the potential to further close the gap with bariatric surgery outcomes
Calorie-Controlled, Nutrient-Dense Nutrition Whole foods: vegetables, fruits, lean protein, complex carbohydrates Calorie targets set to the individual, not to a template Balanced macronutrient distribution appropriate to the patient Referral to a registered dietitian where indicated Regular Physical Activity 150300 minutes per week of moderate-intensity activity brisk walking, swimming, cycling Two to three resistance training sessions per week to preserve lean mass, which matters enormously on GLP-1s Low-impact work such as yoga or Pilates for adherence and mobility Behavioral Support Identifying and addressing emotional eating triggers Building coping strategies that arent food Mindful and intuitive eating practices Realistic, incremental goal setting Ongoing Medical Supervision Monitoring progress and adjusting the plan as physiology and adherence change Screening and treating underlying contributors thyroid dysfunction, insulin resistance, medication effects, hormonal factors Managing pharmacotherapy titration and side effects Verifying that any adjunct, including lipotropics, is actually justified for that patient Hormonal status is frequently the missing variable in a stalled weight loss patient, which is why many weight management practices pair their program with hormone optimization our overview of synthetic versus bioidentical hormones and our hormone pellet and BHRT training cover that side of the practice
L.SulaimanM
Currently, GHK-Cu is being investigated for its potential role in studies involving skin regeneration models, wound-healing pathways, hair follicle signaling, and age-related tissue decline
